{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"25.9","upperLimit":"35.5","value":"30.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"370"}],"units":"Participants"}],"description":"ORR was determined in all participants and was defined as the percentage of participants who had a confirmed Complete Response (CR: complete disappearance of all lesions and no new lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per modified RECIST as assessed by Blinded Independent Central Review (BICR). Modified RECIST differs from RECIST 1.1 in that progressive disease requires confirmation by a repeat radiological assessment no less than 4 weeks from the date of first documented progressive disease. Participants with missing data were considered non-responders. Per protocol, only data generated during the initial course of treatment contributed to the analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 2 years. Eligible participants who stopped the initial course of pembrolizumab due to complete response (CR) or completed initial course of pembrolizumab and had stable disease but progressed after discontinuation, initiated a second course of pembrolizumab at the investigator's discretion for up to an additional year.","id":"OG000","title":"Pembrolizumab 200 mg"}],"paramType":"NUMBER","populationDescription":"All participants who received at least one dose of study treatment during the initial course of treatment","reportingStatus":"POSTED","timeFrame":"Up to approximately 80.5 months","title":"Objective Response Rate (ORR) Per Modified Response Evaluation Criteria in Solid Tumors (Modified RECIST) in All Participants","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Percentage of participants"}